Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tadaharu Goto Appointed New JPMA Director General
September 27, 2010
- Eisai to Apply for Eszopiclone within FY2010
September 27, 2010
- Mediceo Encourages Its MSs to Take Exam for MR Certification
September 27, 2010
- Agensys Begins PI for AGS-16M8F for RCC
September 27, 2010
- JMHA to Jointly Purchase Drugs
September 20, 2010
- Takara Bio Licenses Nucleic Acid Refining Reagent from Macherey-Nagel
September 20, 2010
- Eisai Launches Glufast in China
September 20, 2010
- Rivaroxaban Non-Inferior to Standard Therapy: Bayer
September 20, 2010
- Sawai Prepares for Biosimilars Business
September 20, 2010
- Apixaban More Effective than Aspirin in AF: BMS/Pfizer
September 20, 2010
- Sandoz to Expand Range of Target Doctors for Somatropin Biosimilars
September 20, 2010
- JSNM to Promote Use of PET Drugs for Drug Discovery
September 20, 2010
- JGA to Stress That Equivalence Data Are Unnecessary for Generic IV Injectables
September 20, 2010
- Taxotere to Change Its Name to Prevent Mix-Ups with Taxol
September 20, 2010
- Pharmacists to No Longer Be Held Responsible for ADRs Due to Generic Substitution: JPA Vice President
September 20, 2010
- Korosho to Undertake Surveillance on Multi-Drug-Resistant Bacteria
September 20, 2010
- 12 APIs Included in NHI Price List
September 20, 2010
- TUS Research Team Develops Technology to Make Impurity-Free NSAIDs
September 20, 2010
- Chuikyo to Reconsider 14-Day Limit on Prescription of New Combination Drugs
September 20, 2010
- Telmisartan + Amlodipine More Effective than Either Drug Alone
September 20, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…